PT1982190E - Composições farmacêuticas e métodos de vacinação contra a candidíase disseminada e outros agentes infecciosos - Google Patents

Composições farmacêuticas e métodos de vacinação contra a candidíase disseminada e outros agentes infecciosos Download PDF

Info

Publication number
PT1982190E
PT1982190E PT07709622T PT07709622T PT1982190E PT 1982190 E PT1982190 E PT 1982190E PT 07709622 T PT07709622 T PT 07709622T PT 07709622 T PT07709622 T PT 07709622T PT 1982190 E PT1982190 E PT 1982190E
Authority
PT
Portugal
Prior art keywords
candida
ais
albicans
vaccine
ralslp
Prior art date
Application number
PT07709622T
Other languages
English (en)
Portuguese (pt)
Inventor
John E Edwards
Scott G Filler
Ashraf Ibrahim
Yue Fu
Brad J Spellberg
Michael Yeaman
Original Assignee
Los Angeles Biomed Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomed Res Inst filed Critical Los Angeles Biomed Res Inst
Publication of PT1982190E publication Critical patent/PT1982190E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT07709622T 2006-01-06 2007-01-05 Composições farmacêuticas e métodos de vacinação contra a candidíase disseminada e outros agentes infecciosos PT1982190E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/327,197 US20070077256A1 (en) 1999-11-19 2006-01-06 Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents

Publications (1)

Publication Number Publication Date
PT1982190E true PT1982190E (pt) 2012-10-22

Family

ID=38256965

Family Applications (1)

Application Number Title Priority Date Filing Date
PT07709622T PT1982190E (pt) 2006-01-06 2007-01-05 Composições farmacêuticas e métodos de vacinação contra a candidíase disseminada e outros agentes infecciosos

Country Status (10)

Country Link
US (5) US20070077256A1 (https=)
EP (4) EP1982190B1 (https=)
JP (3) JP5692963B2 (https=)
AU (1) AU2007205065B2 (https=)
CA (2) CA2636277C (https=)
CY (1) CY1113693T1 (https=)
DK (1) DK1982190T3 (https=)
ES (3) ES2608354T3 (https=)
PT (1) PT1982190E (https=)
WO (1) WO2007081896A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) * 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US20060083750A1 (en) * 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US8541008B2 (en) * 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
WO2011003085A1 (en) * 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
GEP201706766B (en) * 2011-07-22 2017-10-25 Los Angeles Biomedical Res Center Methods and compositions for vaccinating against staphylococcus aureus
US10130691B2 (en) 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
JP6566616B2 (ja) * 2014-08-19 2019-08-28 キヤノン株式会社 通信装置、その制御方法、およびプログラム
US20200155449A1 (en) 2015-11-16 2020-05-21 Medincell Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
EP3426287A4 (en) * 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
US10308571B2 (en) * 2017-10-11 2019-06-04 Uop Llc Process for minimizing benzene, toluene, and a recycle loop in a zero benzene aromatics complex
JP7439371B2 (ja) * 2018-04-10 2024-02-28 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー－ ユーシーエルエー メディカル センター Ｃａｎｄｉｄａ ａｕｒｉｓ感染症の治療方法
EP3552620A1 (en) * 2018-04-11 2019-10-16 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods of treatment for candida auris infections
US20220354935A1 (en) * 2021-04-21 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Vaccination against fungal epitopes to prevent inflammatory bowel diseases
WO2025248488A1 (en) * 2024-05-29 2025-12-04 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Compositions and methods for preventing and treating healthcare-associated candida auris infections with dual antigen vaccine

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346074A (en) 1978-08-24 1982-08-24 National Research Development Corp. Pasteurellosis vaccines
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995031998A1 (en) 1994-05-23 1995-11-30 The Research & Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
US6500438B2 (en) 1995-06-07 2002-12-31 Pfizer Incorporated In ovo vaccination against coccidiosis
DE69734601T2 (de) * 1996-05-16 2006-08-03 The Texas A & M University System, College Station Zusammensetzung von kollagenbindungsprotein und verfahren zu deren verwendungen
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US8541008B2 (en) 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US20060083750A1 (en) * 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
EP2319301B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
AU2003231818B2 (en) 2002-05-21 2007-04-19 Intervet International B.V. Methods for the in vitro culture of Sporozoea sp. and user thereof
US7241613B1 (en) 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
AU2003290867A1 (en) * 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
MXPA06005639A (es) 2003-11-21 2006-08-17 Pfizer Prod Inc Adyuvante antimicrobiano.
US20050287146A1 (en) * 2003-12-19 2005-12-29 Joseph Patti Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2006036817A2 (en) 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
WO2007126813A2 (en) 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
BRPI0711572A2 (pt) 2006-04-17 2011-11-16 Schering Plough Ltd organismos recombinantes atenuados de clostridium e vacinas
EP2164511A1 (en) 2007-05-22 2010-03-24 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
US9050281B2 (en) 2008-05-29 2015-06-09 Intervet Inc. Coccidiosis vaccines
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
WO2011003085A1 (en) 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
GEP201706766B (en) * 2011-07-22 2017-10-25 Los Angeles Biomedical Res Center Methods and compositions for vaccinating against staphylococcus aureus
BR112014005773A2 (pt) 2011-09-14 2019-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center composições derivadas de hyr1 e métodos of tratamento usando as mesmas
WO2014144024A1 (en) 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 compositions and methods for treating fungal and bacterial pathogens
US20160030533A1 (en) 2013-03-15 2016-02-04 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods of treating fungal and bacterial pathogens
US10130691B2 (en) 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
EP3426287A4 (en) 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis

Also Published As

Publication number Publication date
CA2636277A1 (en) 2007-07-19
AU2007205065A1 (en) 2007-07-19
EP1982190A2 (en) 2008-10-22
JP2012255031A (ja) 2012-12-27
ES2608354T3 (es) 2017-04-10
US20120014995A1 (en) 2012-01-19
CA2948424A1 (en) 2007-07-19
JP2014148547A (ja) 2014-08-21
EP2428800B1 (en) 2016-09-28
US10300120B2 (en) 2019-05-28
DK1982190T3 (da) 2012-10-22
US20090297562A1 (en) 2009-12-03
EP2532360B1 (en) 2016-09-28
ES2391580T3 (es) 2012-11-28
WO2007081896A3 (en) 2007-11-22
AU2007205065B2 (en) 2013-10-31
ES2608309T3 (es) 2017-04-07
CA2636277C (en) 2017-06-13
JP2009524601A (ja) 2009-07-02
WO2007081896A2 (en) 2007-07-19
CY1113693T1 (el) 2016-06-22
EP2532361A1 (en) 2012-12-12
EP1982190A4 (en) 2009-12-23
JP5692963B2 (ja) 2015-04-01
US20140037689A1 (en) 2014-02-06
EP2532360A1 (en) 2012-12-12
EP1982190B1 (en) 2012-07-18
US20070077256A1 (en) 2007-04-05
EP2428800A1 (en) 2012-03-14
JP5775044B2 (ja) 2015-09-09
US20160220648A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
US10300120B2 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
Sui et al. The vaccines and antibodies associated with Als3p for treatment of Candida albicans infections
EP2448959B1 (en) Hyr1 as a target for active and passive immunization against candida
US20030124134A1 (en) Pharmaceutical compositions and methods to vaccinate against candidiasis
AU2006244401B2 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
AU2013203750A1 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
AU2012216520A1 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents